The Mayo Clinic Cancer Center (MCCC) oversees clinical trial conduct and participant safety of cancer clinical trials conducted at Mayo Clinic through the center's Data and Safety Monitoring (DSM) system. Data and safety monitoring is required for all types of clinical trials (pilot and phase l - lll ) . Monitoring of studies is proportionate to the risk associated with each study. Per NIH policy, a Data and Safety Monitoring Board (DSMB) is established for multi-site clinical trials involving interventions that entail potential risks to participants. The DSM system is in place and provides oversight of clinical research conducted through the MCCC. The process of oversight has been developed to ensure patient safety while promoting research with a high level of quality and integrity. The system is constructed in a manner that promotes ongoing review of each of the components. This permits timely changes in procedures and policies as the regulatory environment changes. It also provides a mechanism to identify internal areas of inconsistency, promoting modifications to the MCCC procedures to address these issues. DSM activities are accomplished through the center's Data and Safety Monitoring Board (DSMB) and Data and Safety Monitoring Committee (DSMC). The Data and Safety Monitoring Committee (DSMC) operates as a component of the DSM system and provides oversight related to the review of changes for investigator brochures, deviation reporting, and the review of adverse events across studies that require changes to the informed consent form. As opposed to the DSMB focus on elements of safety of individual trials, the DSMC is an added value service to investigators in that adverse events across studies for any given agent and investigator brochure (IB) changes that would mandate consent form or protocol procedure changes are identified and addressed to ensure consistency, standardization, and efficiencies. The Data and Safety Monitoring Board (DSMB) operates as a component of the DSM system and is structured to serve all pilot, phase I, II, and III interventional trials for which a DSMB does not exist and for which Mayo is the data center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-40
Application #
8682948
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-04-25
Project End
2019-02-28
Budget Start
2014-07-11
Budget End
2015-02-28
Support Year
40
Fiscal Year
2014
Total Cost
$86,097
Indirect Cost
$32,002
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Dasari, Surendra; Newsom, Sean A; Ehrlicher, Sarah E et al. (2018) Remodeling of skeletal muscle mitochondrial proteome with high-fat diet involves greater changes to ?-oxidation than electron transfer proteins in mice. Am J Physiol Endocrinol Metab 315:E425-E434
Nowsheen, Somaira; Aziz, Khaled; Aziz, Asef et al. (2018) L3MBTL2 orchestrates ubiquitin signalling by dictating the sequential recruitment of RNF8 and RNF168 after DNA damage. Nat Cell Biol 20:455-464
Razidlo, Gina L; Burton, Kevin M; McNiven, Mark A (2018) Interleukin-6 promotes pancreatic cancer cell migration by rapidly activating the small GTPase CDC42. J Biol Chem 293:11143-11153
Wu, Dongyan; Yang, Haitao; Winham, Stacey J et al. (2018) Mediation analysis of alcohol consumption, DNA methylation, and epithelial ovarian cancer. J Hum Genet 63:339-348
Leon-Ferre, Roberto A; Polley, Mei-Yin; Liu, Heshan et al. (2018) Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Res Treat 167:89-99
Jahanseir, Khadijeh; Xing, Deyin; Greipp, Patricia T et al. (2018) PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants. Int J Gynecol Pathol 37:537-546
Painter, Jodie N; O'Mara, Tracy A; Morris, Andrew P et al. (2018) Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Med 7:1978-1987
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2018) DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 128:2376-2388
Sugihara, Takaaki; Werneburg, Nathan W; Hernandez, Matthew C et al. (2018) YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. Mol Cancer Res 16:1556-1567

Showing the most recent 10 out of 1129 publications